NCT01449240已完成不适用
A Cerebrospinal Fluid Collection Study in Pediatric and Adult Patients With Hunter Syndrome
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Shire
- 入组人数
- 10
- 试验地点
- 7
- 主要终点
- Levels of Total Glycosaminoglycan (GAG) in CSF
研究概览
简要总结
The purpose of the study is to collect data on CSF biomarkers in patients with Hunter Syndrome that would serve as reference data for comparison with cognitively impaired patients with Hunter syndrome, patients with other lysosomal storage diseases, or other diseases with CNS involvement.
详细描述
To determine levels of glycosaminoglycans (GAGs), including dermatan sulfate (DS) and heparan sulfate (HS), GAG-degradation products, and other biomarkers of central nervous system (CNS) and lysosomal function in cerebrospinal fluid (CSF) in pediatric and adult patients with Hunter syndrome.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- — 至 70 Years（Child, Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •The patient is male and has a documented diagnosis of Hunter syndrome (MPSII).
- •The adult patient has completed a cognitive assessment at screening/baseline or within the previous 3 months and has been determined to have an intelligence quotient (IQ) ≥
- •Note: cognitive evaluation of pediatric patients is not required.
- •The adult patient or the adult patient's legally authorized representative(s) has voluntarily signed an Institutional Review Board/Independent Ethics Committee-approved informed consent form after all relevant aspects of the study have been explained and discussed.
- •The pediatric patient must be scheduled to undergo a non-study related lumbar puncture or other medical or diagnostic procedure that requires the administration of general anesthesia. The pediatric patient's parent(s) or legally authorized representative(s) must have provided written informed consent (with patient assent as relevant), after all relevant aspects of the study have been explained and discussed, to allow CSF sample collection for this study in conjunction with performance of the non-study related procedure requiring general anesthesia.
排除标准
- •The patient has a history of complications from a previous lumbar puncture(s) or technical challenges in conducting lumbar puncture.
- •The patient has received a hematopoietic stem cell transplant.
- •The patient has taken aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), or other over-the-counter or prescription medications that could affect blood clot formation within the 7 days prior to lumbar puncture, or has ingested such medications within 7 days prior to any study-related procedure in which a change in potential blood clot formation would be deleterious.
- •The patient is currently receiving treatment with intrathecal idursulfase-IT.
- •The patient is currently enrolled in an interventional clinical trial.
- •The patient has participated in a clinical trial of any investigational drug, including idursulfase-IT, or device within the 30 days prior to study entry.
结局指标
主要结局
Levels of Total Glycosaminoglycan (GAG) in CSF
时间窗: Day 1
The concentration of total GAG, including heparan sulfate (HS) and dermatan sulfate (DS) oligosaccharides, in CSF was measured using an enzymatic assay.
次要结局
- Levels of GAG in Urine(Day 1)
研究者
研究点 (7)
Loading locations...
相似试验
已完成
不适用
Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase®Hunter SyndromeNCT00937794Shire33
进行中（未招募）
2 期
Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy ExtensionGaucher Disease Type 1Gaucher Disease Type 3NCT02843035Genzyme, a Sanofi Company12
终止
不适用
Collection of Cerebrospinal Fluid in Healthy ChildrenLate Infantile Neuronal Ceroid LipofuscinosisBatten DiseaseNCT01698229Weill Medical College of Cornell University32
已完成
不适用
Identification of Biomarkers in Spinocerebellar Ataxia 3Spinocerebellar Ataxia Type 3NCT03885167University of Michigan22
招募中
不适用
CSF Biomarkers in Idiopathic Intracranial HypertensionIntracranial HypertensionNCT05647837Assiut University50